• Maintain Buy; Hike target price to Rs 2,450 from Rs 1,665
• Improved business outlook on the back of new launches and operational efficiencies
• Next trigger would likely be the launch of two oncology drugs
• VRS event to lead to cost savings and boost productivity
Comments
Post a Comment